Articles > research
The T1D Exchange Registry is a collection of individuals with type 1 diabetes and their supporters who participate in research. Adults with type 1 diabetes or parents of children with type 1 diabetes can join by registering online, providing consent, and completing a short 28-question survey. Participants will then be asked to complete a similar questionnaire once a year. Once registered, participants will also have the ability to take part in more research opportunities in the future.
We wanted to share some information with you about a new research study. The Type 1 Diabetes EXercise Initiative is a 4-week at-home study. We hope that the study will help us learn how blood sugar changes during exercise in people with type 1 diabetes. If you join the study, you will be asked to …
Sanofi, the French pharmaceutical giant which manufactures the long-acting insulin Lantus, announced Monday that it would no longer be investing in research for new drugs to treat diabetes. The manufacturer also told investors it would no longer be investigating new treatments for cardiovascular health. “To be out of cardiovascular and diabetes is not easy for …
T1D Exchange is conducting interviews with caregivers of people with type 1 diabetes who are 55 and over in the United States. The interview will be a semi-structured one-to-one phone interview with a diabetes professional to discuss your perspective and experience providing care for adult patients with type 1 diabetes.
As important, but perhaps less broadly publicized than the financial burden, is the daily mental and logistical toll diabetes exacts on patients and families. Diabetes affects more than simply blood sugars - it also disrupts sleep, work schedules, social life, and more.
Unfortunately for young people with type 1 diabetes, we still don't have a straightforward screening or genetic test for the disease, which has both environmental and complex hereditary components. A research team at UVA is working to change that.
A new study published in the New England Journal of Medicine (NEJM) showed promising results for closed-loop insulin delivery systems, the journal and participating manufacturers reported last week.